EGFR and neoplasm: One model, DFCI81, was established from the tumor-derived cell line of a patient who developed acquired resistance after an initial long-term response to treatment with EGFR-targeted therapy, whereas the other two models, DFCI161 and DFCI307, exhibited de novo resistance to EGFR TKI (Fig. 1A).